Cisplatin cytotoxicity associated with tetracycline resistance determinants in Escherichia coli

Thesis (Ph. D. in Molecular and Systems Toxicology and Pharmacology)--Massachusetts Institute of Technology, Biological Engineering Division, 2005.

Bibliographic Details
Main Author: Froim, Doriana, 1973-
Other Authors: John M. Essigmann.
Format: Thesis
Language:eng
Published: Massachusetts Institute of Technology 2008
Subjects:
Online Access:http://dspace.mit.edu/handle/1721.1/35701
http://hdl.handle.net/1721.1/35701
_version_ 1826201789668524032
author Froim, Doriana, 1973-
author2 John M. Essigmann.
author_facet John M. Essigmann.
Froim, Doriana, 1973-
author_sort Froim, Doriana, 1973-
collection MIT
description Thesis (Ph. D. in Molecular and Systems Toxicology and Pharmacology)--Massachusetts Institute of Technology, Biological Engineering Division, 2005.
first_indexed 2024-09-23T11:56:56Z
format Thesis
id mit-1721.1/35701
institution Massachusetts Institute of Technology
language eng
last_indexed 2024-09-23T11:56:56Z
publishDate 2008
publisher Massachusetts Institute of Technology
record_format dspace
spelling mit-1721.1/357012019-04-12T14:36:12Z Cisplatin cytotoxicity associated with tetracycline resistance determinants in Escherichia coli Froim, Doriana, 1973- John M. Essigmann. Massachusetts Institute of Technology. Biological Engineering Division. Massachusetts Institute of Technology. Biological Engineering Division. Biological Engineering Division. Thesis (Ph. D. in Molecular and Systems Toxicology and Pharmacology)--Massachusetts Institute of Technology, Biological Engineering Division, 2005. Includes bibliographical references. Tetracyclines, a broad-spectrum class of antibiotics, were discovered in the late 1940s, and became widely used because of their important advantages: they are inexpensive, safe, demonstrate good oral absorption, and are active against a broad range of bacterial pathogens. Unfortunately, as with most antibiotics, the emergence of microbial resistance to tetracyclines has become a serious problem. Today, most genera examined have tetracycline-resistant isolates, although the percentage varies according to species and geographic location. Due to the emergence of resistance, tetracyclines are no longer the antibiotics of choice in treatment of many conditions, although they are still extensively used to treat a variety of bacterial infections. Substantial research efforts have been directed towards reversing tetracycline resistance in bacteria. This work describes the development of a novel anti-bacterial treatment for diseases caused by bacteria resistant to tetracycline. It was found that tetracycline-resistant bacteria expressing the TnlO gene of tetracycline resistance, upon induction with tetracycline, became extremely susceptible to destruction by the DNA-damaging anti-cancer drug cisplatin. Tetracycline-resistant bacteria grown in tetracycline and subsequently treated with cisplatin in the presence of tetracycline were killed about 10⁵-fold more effectively than wild-type bacteria and tetracycline-resistant bacteria not exposed to tetracycline. This phenomenon was observed in different strains of tetracycline-resistant E. coli. Other antibiotics tested with respective antibiotic-resistant bacteria did not produce the same effect of sensitization to cisplatin, suggesting a unique relationship among cisplatin, tetracycline and the tetracycline resistance (cont.) gene. It was determined that levels of platinum DNA damage were higher in sensitized tetracycline-resistant cells than in wild-type cells, although total cellular platinum levels in sensitized tetracycline-resistant cells were not increased. At this time, the mechanism of increased DNA damage formation and the mechanism underlying sensitization to cisplatin are still matters of speculation. The experiments reported here, however, demonstrate that cells expressing the genes of tetracycline resistance actually became primary targets for destruction by cisplatin. Based on this study, it is suggested that the therapeutic power of the tetracyclines could be restored and enhanced by using a complementary drug that, in combination with tetracycline, would induce selective destruction of tetracycline-resistant bacteria. by Doriana Froim. Ph.D.in Molecular and Systems Toxicology and Pharmacology 2008-02-28T16:04:04Z 2008-02-28T16:04:04Z 2005 2005 Thesis http://dspace.mit.edu/handle/1721.1/35701 http://hdl.handle.net/1721.1/35701 60504264 eng MIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission. http://dspace.mit.edu/handle/1721.1/35701 http://dspace.mit.edu/handle/1721.1/7582 97 leaves application/pdf Massachusetts Institute of Technology
spellingShingle Biological Engineering Division.
Froim, Doriana, 1973-
Cisplatin cytotoxicity associated with tetracycline resistance determinants in Escherichia coli
title Cisplatin cytotoxicity associated with tetracycline resistance determinants in Escherichia coli
title_full Cisplatin cytotoxicity associated with tetracycline resistance determinants in Escherichia coli
title_fullStr Cisplatin cytotoxicity associated with tetracycline resistance determinants in Escherichia coli
title_full_unstemmed Cisplatin cytotoxicity associated with tetracycline resistance determinants in Escherichia coli
title_short Cisplatin cytotoxicity associated with tetracycline resistance determinants in Escherichia coli
title_sort cisplatin cytotoxicity associated with tetracycline resistance determinants in escherichia coli
topic Biological Engineering Division.
url http://dspace.mit.edu/handle/1721.1/35701
http://hdl.handle.net/1721.1/35701
work_keys_str_mv AT froimdoriana1973 cisplatincytotoxicityassociatedwithtetracyclineresistancedeterminantsinescherichiacoli